Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Is weight loss medication including in usa medical insurance, becoming the strongest 'roadblock' for the Trump team?
"Weight loss duo" leads significant increase.
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Press Release: Viking Mergers & Acquisitions Announces Key Promotions in Florida Division, Showcasing Internal Growth-Focused Culture and Leadership
Express News | US weight loss drug concept stocks rose across the board, with Viking Therapeutics up more than 5%, Altimmune and Eli Lilly and Co up more than 3%, Sorrento Biologicals and Novo-Nordisk A/S up more than 2%. Previously, US President Biden proposed medical
Amgen (AMGN.US) releases mid-term data for weight loss therapy MariTide, with weight loss results comparable to Novartis.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide has achieved significant results in Phase 2 trials.
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
How Is The Market Feeling About Viking Therapeutics?
Viking Therapeutics Analyst Ratings
B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109
Viking Therapeutics: Strong Potential in Obesity and Type 2 Diabetes Market With Innovative VK2735 Program
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics Is Winning New Fans - and Not for Its Weigh-loss Pill
Express News | Viking Therapeutics Shares Rise 4.6% Premarket After Co Presents Detailed Mid-Stage Data for Experimental Liver Disease Drug